Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Progression 64% Improvement Relative Risk HCQ for COVID-19  López et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 72 patients in Spain Lower progression with HCQ (p=0.016) c19hcq.org López et al., Annals of Pediatrics, Nov 2020 Favors HCQ Favors control

Telemedicine follow-ups for COVID-19: experience in a tertiary hospital

López et al., Annals of Pediatrics, doi:10.1016/j.anpedi.2020.10.017
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 72 pediatric patients showing HCQ associated with a shorter duration of fever (p=0.023), less progression (p=0.016), and fewer return visits to the ER (p=0.017).
risk of progression, 64.3% lower, RR 0.36, p = 0.02, treatment 5 of 36 (13.9%), control 14 of 36 (38.9%), NNT 4.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
López et al., 2 Nov 2020, retrospective, Spain, peer-reviewed, 7 authors.
This PaperHCQAll
Seguimiento telemático de COVID-19: experiencia de un hospital terciario
Javier Nogueira López, Carlos Grasa Lozano, Cristina Ots Ruiz, Luis Alonso García, Iker Falces-Romero, Cristina Calvo, Milagros García-López Hortelano
Anales de Pediatría, doi:10.1016/j.anpedi.2020.10.017
Resumen Introducción: El seguimiento telefónico es una posible alternativa para la atención médica de niños con COVID-19. Nuestro objetivo es describir la experiencia del seguimiento telemático realizado en un hospital terciario. Pacientes y métodos: Estudio descriptivo retrospectivo de los niños con diagnóstico confirmado o probable de COVID-19 atendidos en la consulta de seguimiento del Hospital La Paz entre marzo y junio del 2020. Se realizaron llamadas cada 48 h hasta desaparecer los síntomas y posteriormente semanales hasta estar 14 días asintomáticos. Resultados: Se incluyó a 72 niños con una mediana de edad de 83,5 meses (RIC = 16,3-157,5); 46 eran varones (63,9%) y 14 tenían comorbilidades (19,4%); 32 pacientes (44,4%) habían requerido ingreso hospitalario. Se confirmó diagnóstico de COVID-19 en 33 niños por PCR y en 7 por serología. De los confirmados por PCR, seroconvirtió el 67,7%. Se demostraron otras etiologías en 7 pacientes (5 Mycoplasma pneumoniae, uno parvovirus y uno citomegalovirus). La mediana de duración de síntomas fue 25,5 días (RIC = 13,8-37), con mediana de tiempo de seguimiento de 28 días (RIC = 21-39). Se realizó una mediana de 6 llamadas (RIC = 4-8) por niño; 19 pacientes (26,4%) refirieron empeoramiento en el seguimiento, precisando 14 (19,4%) ser revaluados en Urgencias. Un niño necesitó reingresar, siendo la evolución favorable.
References
Bastos, Tavaziva, Abidi, Campbell, Haraoui et al., Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis, BMJ
Bwire, Majigo, Njiro, Mawazo, Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis, J Med Virol, doi:10.1002/jmv.26349
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19, N Engl J Med, doi:10.1056/NEJMoa2019014
Colmenero, Santonja, Alonso-Riaño, Noguera-Morel, Hernández-Martín et al., SARS-CoV-2 endothelial infection causes COVID-19 chilblains: Histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases, Br J Dermatol, doi:10.1111/bjd.19327
Dong, Mo, Hu, Qi, Jiang et al., Epidemiology of COVID-19 among children in China, Pediatrics
Gallais, Velay, Wendling, Nazon, Partisani et al., Intrafamilial Exposure to SARS-CoV-2 induces cellular immune response without seroconversion, medRxiv
Gottlieb, Long, Dermatologic manifestations and complications of COVID-19, Am J Emerg Med
Guessoum, Lachal, Radjack, Carretier, Minassian et al., Adolescent psychiatric disorders during the COVID-19 pandemic and lockdown, Psychiatry Res
Götzinger, Santiago-García, Noguera-Julián, Lanaspa, Lancella et al., COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study, Lancet Child Adolesc Health
Hoang, Chorath, Moreira, Evans, Burmeister-Morton et al., COVID-19 in 7780 pediatric patients: A systematic review, EClinicalMedicine
Li, Yao, Li, Chen, Song et al., Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19, J Med Virol, doi:10.1002/jmv.26349
Meng, Deng, Dai, Meng, COVID-19 and anosmia: A review based on up-to-date knowledge, Am J Otolaryn
Otto, Geoghegan, Posch, Bell, Coffin et al., The epidemiology of SARS-CoV-2 in a Pediatric Healthcare Network in the United States, J Pediatric Infect Dis Soc
Pollán, Pérez-Gómez, Pastor-Barriuso, Oteo, Hernán et al., Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study, Lancet
Poncet-Megemont, Paris, Tronchere, Salazard, Pereira et al., High prevalence of headaches during Covid-19 infection: A retrospective cohort study, Headache, doi:10.1111/head.13923
Recovery Collaborative Group, Horby, Mafham, Linsell, Bell et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Sekine, Perez-Potti, Rivera-Ballesteros, Strålin, Gorin et al., Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19, Cell
Spinato, Fabbris, Polesel, Cazzador, Borsetto et al., Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection, JAMA
Tenforde, Kim, Lindsell, Rose, Shapiro et al., Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a Multistate Health Care Systems Network-United States, MMWR Morb Mortal Wkly Rep
Wajnberg, Mansour, Leven, Bouvier, Patel et al., Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study, Lancet Microbe
Walsh, Jordan, Clyne, Rohde, Drummond et al., SARS-CoV-2 detection, viral load and infectivity over the course of an infection, J Infect
Who Director, General's opening remarks at the media briefing on COVID-19
Who Director, General's opening remarks at the media briefing on COVID-19. 13
Wikramaratna, Paton, Ghafari, Lourenco, Estimating false-negative detection rate of SARS-CoV-2 by RT-PCR
Younes, Al-Sadeq, Al-Jighefee, Younes, Al-Jamal et al., Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2, Viruses
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit